Equities Analysts Issue Forecasts for Kymera Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at B. Riley lowered their Q3 2024 earnings per share (EPS) estimates for Kymera Therapeutics in a note issued to investors on Wednesday, August 7th. B. Riley analyst K. Patel now expects that the company will post earnings per share of ($0.88) for the quarter, down from their prior estimate of ($0.68). B. Riley currently has a “Neutral” rating and a $36.00 target price on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.86) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q4 2024 earnings at ($0.95) EPS, FY2024 earnings at ($3.00) EPS, FY2025 earnings at ($4.19) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($4.69) EPS and FY2028 earnings at ($4.92) EPS.

KYMR has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $43.00 on Monday. The stock’s 50 day moving average is $37.53 and its 200 day moving average is $37.30. The firm has a market cap of $2.64 billion, a P/E ratio of -17.13 and a beta of 2.22. Kymera Therapeutics has a one year low of $9.60 and a one year high of $48.70.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. The company had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The firm’s quarterly revenue was up 55.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.67) earnings per share.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the transaction, the insider now directly owns 95,470 shares in the company, valued at $4,373,480.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joanna Horobin sold 8,500 shares of Kymera Therapeutics stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 502,345 shares of company stock worth $19,279,932. 15.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 5.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company’s stock valued at $135,848,000 after buying an additional 278,287 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock valued at $101,778,000 after buying an additional 72,351 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $792,000. BVF Inc. IL grew its holdings in shares of Kymera Therapeutics by 8.9% during the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after buying an additional 422,797 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Kymera Therapeutics during the first quarter valued at about $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.